Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)
Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patients with AMI...
Gespeichert in:
| Veröffentlicht in: | Catheterization and cardiovascular interventions 2003-11, Vol.60 (3), p.360-367 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 367 |
|---|---|
| container_issue | 3 |
| container_start_page | 360 |
| container_title | Catheterization and cardiovascular interventions |
| container_volume | 60 |
| creator | Montalescot, Gilles Van de Werf, Frans Gulba, Dietrich C. Avezum, Álvaro Brieger, David Kennelly, Brian M. Mazurek, Tomasz Spencer, Frederick White, Kami Gore, Joel M. |
| description | Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in‐hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%) Catheter Cardiovasc Interv 2003;60:360–367. © 2003 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ccd.10653 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71302028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71302028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3913-b97557b9c5564ac3b183ca8cc5eaa6dd23f4ec9cff015e88a40e027d1c3be18d3</originalsourceid><addsrcrecordid>eNp10c1u1DAQB_AIUdFSOPACyBcQPYS14zgf3ErobiNVgCio3CzHmewaEnuxnZZ9Rx4K7ya0J06Zw2_-M_FE0QuC3xKMk4WUbSgyRh9FJ4QlSZwn2ffHc03KNDuOnjr3A2NcZkn5JDomKctJWhQn0Z9rD9orvUZCt2jd76TZWuNBaVTXzaKua4GU3qhGeWV0KNFWeBVaHLpTfoOEHD2gYWeksK0SfRCdsPKAR92CXZt9-BZsgEKDGR2Sxhot7C5YD_Z2P9_od2ipdBusQ501A_IbCOuYJkRaWCvngzfdPO8-AW4Pq7xZfTmvLs6eRUed6B08n7-n0bflxdfqMr76tKqr86tY0pLQuClzxvKmlIxlqZC0IQWVopCSgRBZ2ya0S0GWsuswYVAUIsWAk7wlgQIpWnoavZ5yw1P9GsF5Pignoe-nH-Q5oTjBSRHg2QSlNc5Z6PjWqiEszgnm-9PxcDp-OF2wL-fQsRmgfZDzrQJ4NQPhpOg7K7RU7sGxJMsymga3mNyd6mH3_4m8qj78Gx1PHeGZ4fd9h7A_eZbTnPGbjyte3SxXn9-X17ygfwG4XcTJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71302028</pqid></control><display><type>article</type><title>Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Montalescot, Gilles ; Van de Werf, Frans ; Gulba, Dietrich C. ; Avezum, Álvaro ; Brieger, David ; Kennelly, Brian M. ; Mazurek, Tomasz ; Spencer, Frederick ; White, Kami ; Gore, Joel M.</creator><creatorcontrib>Montalescot, Gilles ; Van de Werf, Frans ; Gulba, Dietrich C. ; Avezum, Álvaro ; Brieger, David ; Kennelly, Brian M. ; Mazurek, Tomasz ; Spencer, Frederick ; White, Kami ; Gore, Joel M. ; GRACE Investigators</creatorcontrib><description>Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in‐hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%) Catheter Cardiovasc Interv 2003;60:360–367. © 2003 Wiley‐Liss, Inc.</description><identifier>ISSN: 1522-1946</identifier><identifier>EISSN: 1522-726X</identifier><identifier>DOI: 10.1002/ccd.10653</identifier><identifier>PMID: 14571488</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Americas - epidemiology ; angioplasty ; Angioplasty, Balloon, Coronary ; Australia - epidemiology ; Biological and medical sciences ; Blood Vessel Prosthesis Implantation ; Cardiology. Vascular system ; Combined Modality Therapy ; Coronary Artery Bypass ; coronary disease ; Coronary Disease - epidemiology ; Coronary Disease - therapy ; Coronary heart disease ; Europe - epidemiology ; Female ; Fibrinolytic Agents - therapeutic use ; Heart ; Hospital Mortality ; Humans ; Incidence ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Myocardial Infarction - epidemiology ; Myocardial Infarction - therapy ; Myocarditis. Cardiomyopathies ; New Zealand - epidemiology ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors ; Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use ; Postoperative Complications - epidemiology ; Postoperative Complications - etiology ; Registries ; Risk Factors ; Stents ; thrombolytic therapy ; Time Factors ; Treatment Outcome</subject><ispartof>Catheterization and cardiovascular interventions, 2003-11, Vol.60 (3), p.360-367</ispartof><rights>Copyright © 2003 Wiley‐Liss, Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2003 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3913-b97557b9c5564ac3b183ca8cc5eaa6dd23f4ec9cff015e88a40e027d1c3be18d3</citedby><cites>FETCH-LOGICAL-c3913-b97557b9c5564ac3b183ca8cc5eaa6dd23f4ec9cff015e88a40e027d1c3be18d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fccd.10653$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fccd.10653$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15266634$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14571488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montalescot, Gilles</creatorcontrib><creatorcontrib>Van de Werf, Frans</creatorcontrib><creatorcontrib>Gulba, Dietrich C.</creatorcontrib><creatorcontrib>Avezum, Álvaro</creatorcontrib><creatorcontrib>Brieger, David</creatorcontrib><creatorcontrib>Kennelly, Brian M.</creatorcontrib><creatorcontrib>Mazurek, Tomasz</creatorcontrib><creatorcontrib>Spencer, Frederick</creatorcontrib><creatorcontrib>White, Kami</creatorcontrib><creatorcontrib>Gore, Joel M.</creatorcontrib><creatorcontrib>GRACE Investigators</creatorcontrib><title>Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)</title><title>Catheterization and cardiovascular interventions</title><addtitle>Cathet. Cardiovasc. Intervent</addtitle><description>Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in‐hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%) Catheter Cardiovasc Interv 2003;60:360–367. © 2003 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Americas - epidemiology</subject><subject>angioplasty</subject><subject>Angioplasty, Balloon, Coronary</subject><subject>Australia - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Blood Vessel Prosthesis Implantation</subject><subject>Cardiology. Vascular system</subject><subject>Combined Modality Therapy</subject><subject>Coronary Artery Bypass</subject><subject>coronary disease</subject><subject>Coronary Disease - epidemiology</subject><subject>Coronary Disease - therapy</subject><subject>Coronary heart disease</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Heart</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Myocardial Infarction - epidemiology</subject><subject>Myocardial Infarction - therapy</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>New Zealand - epidemiology</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use</subject><subject>Postoperative Complications - epidemiology</subject><subject>Postoperative Complications - etiology</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Stents</subject><subject>thrombolytic therapy</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1522-1946</issn><issn>1522-726X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10c1u1DAQB_AIUdFSOPACyBcQPYS14zgf3ErobiNVgCio3CzHmewaEnuxnZZ9Rx4K7ya0J06Zw2_-M_FE0QuC3xKMk4WUbSgyRh9FJ4QlSZwn2ffHc03KNDuOnjr3A2NcZkn5JDomKctJWhQn0Z9rD9orvUZCt2jd76TZWuNBaVTXzaKua4GU3qhGeWV0KNFWeBVaHLpTfoOEHD2gYWeksK0SfRCdsPKAR92CXZt9-BZsgEKDGR2Sxhot7C5YD_Z2P9_od2ipdBusQ501A_IbCOuYJkRaWCvngzfdPO8-AW4Pq7xZfTmvLs6eRUed6B08n7-n0bflxdfqMr76tKqr86tY0pLQuClzxvKmlIxlqZC0IQWVopCSgRBZ2ya0S0GWsuswYVAUIsWAk7wlgQIpWnoavZ5yw1P9GsF5Pignoe-nH-Q5oTjBSRHg2QSlNc5Z6PjWqiEszgnm-9PxcDp-OF2wL-fQsRmgfZDzrQJ4NQPhpOg7K7RU7sGxJMsymga3mNyd6mH3_4m8qj78Gx1PHeGZ4fd9h7A_eZbTnPGbjyte3SxXn9-X17ygfwG4XcTJ</recordid><startdate>200311</startdate><enddate>200311</enddate><creator>Montalescot, Gilles</creator><creator>Van de Werf, Frans</creator><creator>Gulba, Dietrich C.</creator><creator>Avezum, Álvaro</creator><creator>Brieger, David</creator><creator>Kennelly, Brian M.</creator><creator>Mazurek, Tomasz</creator><creator>Spencer, Frederick</creator><creator>White, Kami</creator><creator>Gore, Joel M.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200311</creationdate><title>Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)</title><author>Montalescot, Gilles ; Van de Werf, Frans ; Gulba, Dietrich C. ; Avezum, Álvaro ; Brieger, David ; Kennelly, Brian M. ; Mazurek, Tomasz ; Spencer, Frederick ; White, Kami ; Gore, Joel M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3913-b97557b9c5564ac3b183ca8cc5eaa6dd23f4ec9cff015e88a40e027d1c3be18d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Americas - epidemiology</topic><topic>angioplasty</topic><topic>Angioplasty, Balloon, Coronary</topic><topic>Australia - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Blood Vessel Prosthesis Implantation</topic><topic>Cardiology. Vascular system</topic><topic>Combined Modality Therapy</topic><topic>Coronary Artery Bypass</topic><topic>coronary disease</topic><topic>Coronary Disease - epidemiology</topic><topic>Coronary Disease - therapy</topic><topic>Coronary heart disease</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Heart</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Myocardial Infarction - epidemiology</topic><topic>Myocardial Infarction - therapy</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>New Zealand - epidemiology</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use</topic><topic>Postoperative Complications - epidemiology</topic><topic>Postoperative Complications - etiology</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Stents</topic><topic>thrombolytic therapy</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montalescot, Gilles</creatorcontrib><creatorcontrib>Van de Werf, Frans</creatorcontrib><creatorcontrib>Gulba, Dietrich C.</creatorcontrib><creatorcontrib>Avezum, Álvaro</creatorcontrib><creatorcontrib>Brieger, David</creatorcontrib><creatorcontrib>Kennelly, Brian M.</creatorcontrib><creatorcontrib>Mazurek, Tomasz</creatorcontrib><creatorcontrib>Spencer, Frederick</creatorcontrib><creatorcontrib>White, Kami</creatorcontrib><creatorcontrib>Gore, Joel M.</creatorcontrib><creatorcontrib>GRACE Investigators</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Catheterization and cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montalescot, Gilles</au><au>Van de Werf, Frans</au><au>Gulba, Dietrich C.</au><au>Avezum, Álvaro</au><au>Brieger, David</au><au>Kennelly, Brian M.</au><au>Mazurek, Tomasz</au><au>Spencer, Frederick</au><au>White, Kami</au><au>Gore, Joel M.</au><aucorp>GRACE Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)</atitle><jtitle>Catheterization and cardiovascular interventions</jtitle><addtitle>Cathet. Cardiovasc. Intervent</addtitle><date>2003-11</date><risdate>2003</risdate><volume>60</volume><issue>3</issue><spage>360</spage><epage>367</epage><pages>360-367</pages><issn>1522-1946</issn><eissn>1522-726X</eissn><abstract>Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in‐hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%) Catheter Cardiovasc Interv 2003;60:360–367. © 2003 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>14571488</pmid><doi>10.1002/ccd.10653</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-1946 |
| ispartof | Catheterization and cardiovascular interventions, 2003-11, Vol.60 (3), p.360-367 |
| issn | 1522-1946 1522-726X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71302028 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Americas - epidemiology angioplasty Angioplasty, Balloon, Coronary Australia - epidemiology Biological and medical sciences Blood Vessel Prosthesis Implantation Cardiology. Vascular system Combined Modality Therapy Coronary Artery Bypass coronary disease Coronary Disease - epidemiology Coronary Disease - therapy Coronary heart disease Europe - epidemiology Female Fibrinolytic Agents - therapeutic use Heart Hospital Mortality Humans Incidence Male Medical sciences Middle Aged Multivariate Analysis Myocardial Infarction - epidemiology Myocardial Infarction - therapy Myocarditis. Cardiomyopathies New Zealand - epidemiology Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use Postoperative Complications - epidemiology Postoperative Complications - etiology Registries Risk Factors Stents thrombolytic therapy Time Factors Treatment Outcome |
| title | Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A41%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stenting%20and%20glycoprotein%20IIb/IIIa%20inhibition%20in%20patients%20with%20acute%20myocardial%20infarction%20undergoing%20percutaneous%20coronary%20intervention:%20Findings%20from%20the%20global%20registry%20of%20acute%20coronary%20events%20(GRACE)&rft.jtitle=Catheterization%20and%20cardiovascular%20interventions&rft.au=Montalescot,%20Gilles&rft.aucorp=GRACE%20Investigators&rft.date=2003-11&rft.volume=60&rft.issue=3&rft.spage=360&rft.epage=367&rft.pages=360-367&rft.issn=1522-1946&rft.eissn=1522-726X&rft_id=info:doi/10.1002/ccd.10653&rft_dat=%3Cproquest_cross%3E71302028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71302028&rft_id=info:pmid/14571488&rfr_iscdi=true |